Anything less than $71 per share from J&J should not be accepted, in our view.
Elliott is extremely disappointed in your decision to accept a revised Johnson & Johnson offer that clearly fails to maximize shareholder value, and is appalled at the board's failure to stand up for the shareholders you are charged to represent.
We ask that you declare any subsequent offer with improved terms from Boston Scientific as superior.
This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.
This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.